Resources>Blog>How Biointron Delivers Results in Just 2 Weeks

How Biointron Delivers Results in Just 2 Weeks

Biointron 2025-01-13 Read time: 2 mins

Antibody_IgG1_surface

Biointron, established in 2012 and ISO 9001:2015 certified, is a leading Contract Research Organization (CRO) specializing in antibody discovery, optimization, and expression services for biotech and pharmaceutical companies worldwide.

Leveraging over a decade of experience, we have developed a high-throughput (HTP) recombinant antibody production platform that delivers purified antibodies from gene sequences in just two weeks.

This accelerated timeline is achieved through a streamlined workflow encompassing in-house gene synthesis, plasmid construction, transient expression in HEK293 or CHO cells, and stringent quality control measures. The process begins with codon optimization and gene synthesis, followed by subcloning into an expression vector. After plasmid amplification, transient transfection of mammalian cells is performed, leading to antibody expression and subsequent purification. Quality control includes SDS-PAGE analysis to ensure purity exceeds 95%, low endotoxin levels, and size-exclusion high-performance liquid chromatography (SEC-HPLC) detection.

Our commitment to rapid and reliable antibody production has attracted over 2,000 global biotech and pharmaceutical partners, including industry leaders such as AstraZeneca, AbbVie, Moderna, Sanofi, and Merck KGaA. These collaborations underscore Biointron's reputation for delivering high-quality antibodies with minimal batch-to-batch variation, meeting stringent industry standards.

In addition to recombinant antibody production, we offer a comprehensive suite of services, including bispecific antibody production, large-scale antibody production, protein expression in mammalian systems, single B-cell screening, CHO-K1 stable cell line generation, VHH antibody discovery, antibody humanization, and affinity maturation. This extensive service portfolio positions Biointron as a one-stop solution for antibody discovery and optimization needs.

Biointron's dedication to excellence, customer-centric approach, and passion for advancing biotechnology make it a trusted partner for researchers and developers seeking efficient and high-quality antibody solutions. Contact us at info@biointron.com or +1 (732) 790-8340.


Subscribe to our Blog
Recommended Articles
Overview of N-linked Glycosylation in IgG Antibodies

Monoclonal antibodies (mAbs), particularly IgGs, are among the most successful t……

Jun 25, 2025
AIS 2025 – France: Highlights and Event Recap

The 13th Antibody Industrial Symposium 2025 was held in Tours, France, from June……

Jun 22, 2025
Antibody and ADC Therapeutics Xchanges – Boston 2025: Event Recap

hubXchange's Antibody Drug Conjugates Therapeutics Xchange and Antibody Therapeu……

Jun 19, 2025
BIO 2025 – Boston: Highlights and Event Recap

The BIO International Convention 2025 was held in Boston, MA from June 16-19 It ……

Jun 16, 2025

Our website uses cookies to improve your experience. Read our Privacy Policy to find out more.